Story

Memorises Bio was carved out from Memo Therapeutics AG in 2026, as part of Memo’s acquisition by Ipsen. We carry forward the antibody discovery platform and research activities outside the potravitug program, including the collaboration with CSL on recombinant polyclonal IgG.